Absynth Biologics

Absynth is developing vaccines and antibodies to prevent and treat bacterial infections with a distinctive technology platform for identifying proprietary antigens that harness the immune system more effectively than other antigens, to stimulate a host protective response. Antimicrobial resistance constitutes a serious danger to public health, which has been acknowledged by the USA Centers for Diseases Control & Prevention and the European Centre for Disease Prevention and Control. Bacterial vaccines have the potential to reduce community reliance on antibiotics and there is evidence that vaccines can contribute to decreased antibiotic usage. 

Absynth has used its technology platform to establish a vaccine pipeline targeting pathogens for substantial markets, in which no marketed vaccines exist. The most advanced vaccine programme targets Staphylococcus aureus, while pipeline vaccine programmes target Clostridium difficile and Streptococcus pyogenes. The Company also has a S. aureus antibody programme in preclinical research. The Company’s approach has the potential to overcome previous limitations through its novel antigens, as well as its innovative approach to using in vivo models and correlates of infection for candidate optimization and selection. Six patent families are filed from which eleven patents have granted.

Organisation type
Keywords
Vaccines, anti-infectives, anti-bacterials, anti-infective antibodies
Membership affiliation
Dr Fiona Marston
Dr Fiona Marston
Chief Executive 
Dr Anthony Upton
Head of Development 

Appleyard Lees

Appleyard Lees is a highly respected and leading firm of European Patent and Trade Mark Attorneys.

They have an experienced life science and chemical team and an enviable reputation of working with some of the most innovative organisations in the UK and around the world.  Acting for a range of clients, including well-known multinational corporations, Universities and SMEs, they have earned a reputation for not only handling complex technical subject matter, but also providing clear and strategic advice.

Appleyard Lees have offices throughout the UK and also in Munich and The Hague.  They are listed in Chambers UK, the Legal500 and Managing IP ‘IP Stars’.

Membership affiliation
Keywords
patent attorney,trade marks
Organisation type
Mr Simon Bradbury
Mr Simon Bradbury
Patent Attorney & Head of Life Sciences 

Atlantic Healthcare plc

Atlantic is an emerging UK biopharmaceutical company that in-licenses or acquires on a global or major regional basis niche late stage clinical development or heritage marketed products that will be prescribed by specialist hospital physicians.  Atlantic is seeking ex-US licensees for Alicaforsen, its Phase 3 ready anti-inflammatory antisense oligonucleotide indicated for pouchitis (orphan disease) and for active distal colitis.

Website:
atlantichc.com
Organisation type
Membership affiliation
Mr Simon Kerr
Mr Simon Kerr
Director of Business Development 

Autifony Therapeutics Ltd

Autifony Therapeutics is developing pharmaceutical treatments for hearing disorders, which affect a significant proportion of the population. Autifony‘s approach is focused on Kv3 potassium channel modulation, a novel mechanism of action. These ion channels regulate neuronal activity within the auditory system, and our new drugs aim to treat age related hearing loss and tinnitus. The lead programme has completed Phase I clinical trials and is about to start two Phase IIa studies – for age related hearing loss in the US, and for tinnitus in the UK (supported by funding from the Technology Strategy Board).

Given Autifony’s focus on modulation of Kv3 channels, which have also been implicated in other neurological and psychiatric disorders, there are opportunities for Autifony to investigate these other indications with compounds with different profiles. Autifony was awarded Technology Strategy Board funding to progress the development of a candidate drug for the treatment of schizophrenia, working together with academic collaborators at the Universities of Manchester and Newcastle.

Autifony Therapeutics Limited was formed in 2011 as a spin-out from GSK. The company is privately funded by leading venture capital investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments. Autifony’s head office is at the Imperial College Incubator in London, and has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.

Website:
www.autifony.com
Membership affiliation
Keywords
hearing, tinnitus, schizophrenia, CNS, drug discovery, drug development
Organisation type
Dr Barbara Domayne-Hayman
Chief Business Officer